Major stock indexes in the United States have kicked off the new year on a mostly positive note, with the Dow Jones Industrial Average and S&P 500 snapping four-session losing streaks. In such a ...

Shares in British biopharmaceutical firm Mereo Biopharma ($MREO) saw a wipeout of over 90% on Monday after two of its ...

With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming ...

Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta ...

Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.

Shares in Ultragenyx and Mereo BioPharma have plunged after their drug for osteogenesis imperfecta (OI) or brittle bone ...

Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...

Ultragenyx Pharmaceutical and Mereo BioPharma said their two Phase 3 trials for setrusumab to treat rare bone disorder osteogenesis imperfecta, didn't meet their main goal of reducing fracture rates.

As of Monday, December 29, Mereo BioPharma Group plc’s MREO share price has dipped by 89.96%, which has investors questioning ...

Mereo BioPharma’s attempt to appease Rubric Capital Management has failed, with the activist investor rejecting an offer to gain a seat on the board and continuing to push for bigger changes to the ...

US biotech Ultragenyx Pharmaceutical saw its shares tumble over 43% to $19.41 yesterday, after it announced results from the ...